Multiple Myeloma Therapeutics Market Market - Top Companies and Manufacturers

  • Report ID: 6606
  • Published Date: Oct 29, 2024
  • Report Format: PDF, PPT

Companies Dominating the Multiple Myeloma Therapeutics Landscape

    The multiple myeloma therapeutics market is majorly driven by new developments and advanced applications. The industry leaders are now focusing on integrating technologies to expand their portfolio, making MM treatment accessible for patients. This is further creating an opportunity for drug manufacturers to streamline their products. Public and governing authorities are collaborating to realize the concept. For instance, in October 2024, the International Myeloma Foundation collaborated with SparkCures to build a platform to match clinical trials. The platform, myeloma.org. will connect myeloma patients with care partners to discover clinical trials, based on the patient’s health-related information. Such key players in the market include:

    • Service Providers
    • Cleveland Clinic
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Dana-Farber Cancer Institute, Inc.
    • Mayo Foundation for Medical Education and Research (MFMER)
    • MD Anderson Cancer Center
    • Memorial Sloan Kettering Cancer Center

     

    • Medication Manufacturers 
    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Amgen Inc.
    • Bristol-Myers Squibb Company.
    • Glenmark Pharmaceuticals Ltd.
    • Johnson & Johnson Services, Inc
    • Merck & Co, Inc.
    • Novartis AG
    • Sanofi S.A.

Browse Key Market Insights with Data Illustration:

In the News

  • In September 2024, the FDA approved Sarclisa, the first anti-CD38 therapy, launched by Sanfoi for newly diagnosed adult myeloma patients. The therapy is combined with standard-of-care treatment and is dedicated to helping patients, who are not eligible for transplant.
  • In April 2024, Johnson & Johnson got approval from the FDA to release CARVYKTI for treating adult patients. The BCMA-targeted treatment is highly effective for patients with relapsed or refractory multiple myeloma.  

Author Credits:  Radhika Pawar


  • Report ID: 6606
  • Published Date: Oct 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the multiple myeloma therapeutics market was over USD 27.2 billion.

The market size for the multiple myeloma therapeutics market is projected to reach USD 58.5 billion by the end of 2037 expanding at a CAGR of 6.6% during the forecast period i.e., between 2025-2037.

The major players in the market as Service Providers are Cleveland Clinic, Dana-Farber Cancer Institute, Inc., Mayo Foundation for Medical Education and Research (MFMER), MD Anderson Cancer Center, Takeda Pharmaceutical Company Limited, and others.

In terms of treatment type, the targeted therapy segment is anticipated to garner the largest market share of 33.6% by 2037 and display lucrative growth opportunities during 2025-2037.

The market in North America is projected to hold the largest market share of 47.8% by the end of 2037 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample